A Study of LY2157299 in Participants With Hepatocellular Carcinoma


NCT01246986

Interventional

Phase 2

Active, not recruiting
The purpose of this study is to estimate the median time to progression in participants with hepatocellular carcinoma (HCC) when treated with LY2157299 as monotherapy and in combination with sorafenib or ramucirumab.
Mar 30,2011
All
18 Years
N/A
193

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.